Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. reports developments in women's health and family building benefits, including fertility care access, employer demand, product expansion, and financial results. The company provides benefit solutions for employers, health plans, and benefit purchasers, combining concierge support, coaching, education, digital tools, and access to a network of fertility and women's health specialists.
Recurring updates include quarterly earnings, financial guidance, selling-season activity, share repurchases, investor conference appearances, and offerings such as Progyny Select, a fully insured supplemental fertility and family building plan for small U.S. employers.
Progyny (PGNY) will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026, at 11:00 a.m. ET.
The session, led by Chief Financial Officer Mark Livingston, will be webcast live, with audiocasts and replays accessible via the Events and Presentations section of Progyny’s investor relations website.
Progyny (Nasdaq: PGNY) announced that CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays will be accessible via the Events and Presentations section of Progyny’s investor relations website.
Progyny (Nasdaq: PGNY) reported record second quarter 2026 results, with revenue of $350.5 million, up 5.3% year over year (11.0% excluding a non‑renewing large client), and gross profit of $89.3 million, up 13%. Gross margin expanded to 25.5% from 23.7%.
Net income rose to $28.1 million, or $0.34 per diluted share, versus $17.1 million and $0.19 a year ago. Adjusted EBITDA increased to $62.1 million with a 17.7% margin. Progyny ended June 30, 2026 with $236.9 million in cash and marketable securities, no debt, and working capital of $272.9 million, and had 604 fertility and family building clients. The company repurchased nearly 1.2 million shares in Q2 (2.0 million to date under the May 2026 authorization; 10.8 million across current and prior programs) and guided 2026 revenue to $1.36–$1.385 billion and net income to $104.8–$109.9 million.
Progyny (Nasdaq: PGNY) will report its financial results for the quarter ended June 30, 2026 after the market close on Thursday, August 6, 2026. A conference call is scheduled for 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time), with a press release issued before the call.
U.S. participants can join by dialing 1.866.825.7331 (passcode 265484); international participants can dial 1.973.413.6106 (same passcode). A replay will be available through August 13, 2026 at 1.800.332.6854 (U.S.) or 1.973.528.0005 (international) with passcode 265484. A live webcast and archive will be accessible via the Events and Presentations section of Progyny’s investor website.
Progyny (Nasdaq: PGNY) released survey results showing strong demand for personalized, human-led guidance in fertility, pregnancy, postpartum, and menopause care.
71% of members reported added stress from their healthcare journey, 43% said stress hurt work performance, and over 70% wanted trusted human support like Progyny Care Advocates (PCAs).
Progyny (Nasdaq: PGNY) announced that its board approved a share repurchase program authorizing buybacks of up to $200 million of common stock. The program will be funded with available cash and may use open-market and Rule 10b5-1 plans, with timing and size depending on market conditions.
Progyny (Nasdaq: PGNY) announced that CEO Pete Anevski and CFO Mark Livingston will speak in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 11:20 a.m. PT / 2:20 p.m. ET.
A live audiocast and replay will be available on Progyny’s investor relations website.
Progyny (Nasdaq: PGNY) reported record Q1 2026 revenue of $328.5M, gross profit of $83.1M and net income of $24.2M ($0.29 diluted). Adjusted EBITDA was $56.6M. The company repurchased 8.8M shares to date and had 595 clients and ~7.185M average members.
Progyny (NASDAQ: PGNY) will report results for the quarter ended March 31, 2026, after market close on Thursday, May 7, 2026. A conference call will follow at 4:45 p.m. ET (1:45 p.m. PT). A press release will be issued before the call and a live webcast and archived replay will be available on the investor website.
Progyny (Nasdaq: PGNY) launched Progyny Select, the industry’s first fully insured supplemental fertility and women’s health plan for small U.S. employers, announced April 16, 2026. Key features include fixed PEPM pricing, comprehensive coverage (IVF, IUI, genetic testing), concierge care advocates, and support across pregnancy, postpartum, and menopause.
The plan will be distributed via brokers, health plan partners, and agents for implementation in 2027 plan years.